A novel pan-negative-gating modulator of KCa2/3 channels, fluoro-di-benzoate, RA-2, inhibits endothelium-derived hyperpolarization-type relaxation in coronary artery and produces bradycardia in vivo

Molecular Pharmacology

Volumn 87, Issue 2, 2015, Pages 338-348

  Oliván Viguera, Aida ^a   Valero, Marta Sofía ^b   Coleman, Nicole ^c   Brown, Brandon M ^c   Laría, Celia ^b   Murillo, María Divina ^d   Gálvez, José A ^e   Díaz De Villegas, María D ^e   Wulff, Heike ^c   Badorrey, Ramón ^e   Köhler, Ralf ^a,f  

^a HOSPITAL UNIVERSITARIO MIGUEL SERVET   (Spain)

^b UNIVERSIDAD SAN JORGE   (Spain)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSIDAD DE ZARAGOZA   (Spain)

^e CSIC UZA Instituto de Sintesis Quimica y Catalisis Homogenea ISQCH   (Spain)

^f Fundación Agencia Aragonesa Para la Investigación y Desarrollo   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

1,2 PHENYLENEBIS(METHYLENE) BIS(3 FLUORO 4 HYDROXYBENZOATE); 1,3 PHENYLENEBIS(METHYLENE) BIS(3 FLUORO 4 HYDROXYBENZOATE); 1,4 PHENYLENEBIS(METHYLENE) BIS(3 FLUORO 4 HYDROXYBENZOATE); BENZOIC ACID DERIVATIVE; BRADYKININ; CALCIUM ION; POTASSIUM CHANNEL; UNCLASSIFIED DRUG; HYPERPOLARIZATION ACTIVATED CYCLIC NUCLEOTIDE GATED CHANNEL; KCNN2 PROTEIN, HUMAN; KCNN3 PROTEIN, HUMAN; POTASSIUM CHANNEL BLOCKING AGENT; SMALL CONDUCTANCE CALCIUM ACTIVATED POTASSIUM CHANNEL;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD PRESSURE MEASUREMENT; BRADYCARDIA; CARBON NUCLEAR MAGNETIC RESONANCE; CARDIOVASCULAR EFFECT; CONTROLLED STUDY; CORONARY ARTERY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SYNTHESIS; ELECTROPHYSIOLOGY; EMBRYO; ENDOTHELIUM; EX VIVO STUDY; FEMALE; HEART RATE; HUMAN; HUMAN CELL; HYDROLYSIS; HYPERPOLARIZATION; IC50; IN VIVO STUDY; LIPOPHILICITY; LIVER HOMOGENATE; MASS SPECTROMETRY; MEAN ARTERIAL PRESSURE; MOUSE; MYOGRAPHY; NONHUMAN; PATCH CLAMP TECHNIQUE; PHARMACOPHORE; TELEMETRY; WHOLE CELL; ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; CHANNEL GATING; CHEMICALLY INDUCED; CHEMISTRY; CORONARY BLOOD VESSEL; DRUG EFFECTS; HEK293 CELL LINE; KNOCKOUT MOUSE; ORGAN CULTURE TECHNIQUE; PATHOPHYSIOLOGY; PHYSIOLOGY; VASCULAR ENDOTHELIUM; VASODILATATION;

ANIMALS; BENZOATES; BRADYCARDIA; CORONARY VESSELS; ENDOTHELIUM, VASCULAR; FEMALE; HEART RATE; HEK293 CELLS; HUMANS; HYPERPOLARIZATION-ACTIVATED CYCLIC NUCLEOTIDE-GATED CHANNELS; ION CHANNEL GATING; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; ORGAN CULTURE TECHNIQUES; POTASSIUM CHANNEL BLOCKERS; SMALL-CONDUCTANCE CALCIUM-ACTIVATED POTASSIUM CHANNELS; VASODILATION;

EID: 84920589130     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.114.095745     Document Type: Article

References (61)

1. + channels: Form and function. Annu Rev Physiol 74: 245-269.
2. Alda JO, Valero MS, Pereboom D, Gros P, and Garay RP (2009) Endothelium-independent vasorelaxation by the selective alpha estrogen receptor agonist propyl pyrazole triol in rat aortic smooth muscle. J Pharm Pharmacol 61: 641-646.
3. Ataga KI and Stocker J (2009) Senicapoc (ICA-17043): a potential therapy for the prevention and treatment of hemolysis-associated complications in sickle cell anemia. Expert Opin Investig Drugs 18: 231-239.
4. Brähler S, Kaistha A, Schmidt VJ, Wölfle SE, Busch C, Kaistha BP, Kacik M, Hasenau AL, Grgic I, and Si H et al. (2009) Genetic deficit of SK3 and IK1 channels disrupts the endothelium-derived hyperpolarizing factor vasodilator pathway and causes hypertension. Circulation 119: 2323-2332.
5. Cao YJ and Houamed KM (1999) Activation of recombinant human SK4 channels by metal cations. FEBS Lett 446: 137-141.
6. Chantôme A, Potier-Cartereau M, Clarysse L, Fromont G, Marionneau-Lambot S, Guéguinou M, Pagès JC, Collin C, Oullier T, and Girault A et al. (2013) Pivotal role of the lipid Raft SK3-Orai1 complex in human cancer cell migration and bone metastases. Cancer Res 73: 4852-4861.
7. + channel gating modulators with selectivity for KCa3.1. Mol Pharmacol 86: 342-357.
8. D'Alessandro G, Catalano M, Sciaccaluga M, Chece G, Cipriani R, Rosito M, Grimaldi A, Lauro C, Cantore G, and Santoro A et al. (2013) KCa3.1 channels are involved in the infiltrative behavior of glioblastoma in vivo. Cell Death Dis 4: e773.
9. Damkjaer M, Nielsen G, Bodendiek S, Staehr M, Gramsbergen JB, de Wit C, Jensen BL, Simonsen U, Bie P, and Wulff H et al. (2012) Pharmacological activation of KCa3.1/KCa2.3 channels produces endothelial hyperpolarization and lowers blood pressure in conscious dogs. Br J Pharmacol 165: 223-234.
10. + channel. Am J Physiol 271:L775-L784.
11. Díez-Barra E, García-Martínez JC, Merino S, del Rey R, Rodríguez-López J, Sánchez-Verdú P, and Tejeda J (2001) Synthesis, characterization, and optical response of dipolar and non-dipolar poly(phenylenevinylene) dendrimers. J Org Chem 66: 5664-5670.
12. + channels terminates and protects against atrial fibrillation. Circ Arrhythm Electrophysiol 3: 380-390.
13. Edwards G, Félétou M, and Weston AH (2010) Endothelium-derived hyperpolarising factors and associated pathways: a synopsis. Pflugers Arch 459: 863-879.
14. Ellinor PT, Lunetta KL, Glazer NL, Pfeufer A, Alonso A, Chung MK, Sinner MF, de Bakker PI, Mueller M, and Lubitz SA et al. (2010) Common variants in KCNN3 are associated with lone atrial fibrillation. Nat Genet 42: 240-244.
15. Engbers JD, Anderson D, Asmara H, Rehak R, Mehaffey WH, Hameed S, McKay BE, Kruskic M, Zamponi GW, and Turner RW (2012) Intermediate conductance calcium-activated potassium channels modulate summation of parallel fiber input in cerebellar Purkinje cells. Proc Natl Acad Sci USA 109: 2601-2606.
16. Félétou M, Köhler R, and Vanhoutte PM (2010) Endothelium-derived vasoactive factors and hypertension: possible roles in pathogenesis and as treatment targets. Curr Hypertens Rep 12: 267-275.
17. Fisslthaler B, Popp R, Kiss L, Potente M, Harder DR, Fleming I, and Busse R (1999) Cytochrome P450 2C isan EDHF synthase incoronary arteries. Nature 401: 493-497.
18. Ge ZD, Zhang XH, Fung PC, and He GW (2000) Endothelium-dependent hyperpo-larization and relaxation resistance to N(G)-nitro-L-arginine and indomethacin in coronary circulation. Cardiovasc Res 46: 547-556.
19. + channel suppresses proliferation of microvascular and macrovascular endothelial cells and angiogenesis in vivo. Arterioscler Thromb Vasc Biol 25: 704-709.
20. Grgic I, Kiss E, Kaistha BP, Busch C, Kloss M, Sautter J, Müller A, Kaistha A, Schmidt C, and Raman G et al. (2009) Renal fibrosis is attenuated by targeted disruption of KCa3.1 potassium channels. Proc Natl Acad Sci USA 106: 14518-14523.
21. + channels, types Kv1.1, 1.2, 1.3, 1.5, and 3.1, stably expressed in mammalian cell lines. Mol Pharmacol 45: 1227-1234.
22. Ca2.1 subtype. Mol Pharmacol 81: 210-219.
23. Ishii TM, Silvia C, Hirschberg B, Bond CT, Adelman JP, and Maylie J (1997) A human intermediate conductance calcium-activated potassium channel. Proc Natl Acad Sci USA 94: 11651-11656.
24. Ca2 channels. Mol Pharmacol 79: 899-909.
25. + channel KCNN4/KCa3.1 contributes to microglia activation and nitric oxide-dependent neurodegeneration. J Neurosci 27: 234-244.
26. Köhler M, Hirschberg B, Bond CT, Kinzie JM, Marrion NV, Maylie J, and Adelman JP (1996) Small-conductance, calcium-activated potassium channels from mammalian brain. Science 273: 1709-1714.
27. + channels in human mesenteric artery: A single-cell reverse transcriptase-polymerase chain reaction and electro-physiological study in situ. Circ Res 87: 496-503.
28. Ca-channels as therapeutic targets in hypertension and restenosis disease. Expert Opin Ther Targets 14: 143-155.
29. Köhler R, Wulff H, Eichler I, Kneifel M, Neumann D, Knorr A, Grgic I, Kämpfe D, Si H, and Wibawa J et al. (2003) Blockade of the intermediate-conductance calcium-activated potassium channel as a new therapeutic strategy for restenosis. Circulation 108: 1119-1125.
30. Lam J, Coleman N, Garing AL, and Wulff H (2013) The therapeutic potential of small-conductance KCa2 channels in neurodegenerative and psychiatric diseases. Expert Opin Ther Targets 17: 1203-1220.
31. Lambertsen KL, Gramsbergen JB, Sivasaravanaparan M, Ditzel N, Sevelsted-Møller LM, Oliván-Viguera A, Rabjerg M, Wulff H, and Köhler R (2012) Genetic KCa3.1-deficiency produces locomotor hyperactivity and alterations in cerebral monoamine levels. PLoS ONE 7: e47744.
32. Lamoral-Theys D, Pottier L, Kerff F, Dufrasne F, Proutière F, Wauthoz N, Neven P, Ingrassia L, Antwerpen PV, and Lefranc F et al. (2010) Simple di- and trivanillates exhibit cytostatic properties toward cancer cells resistant to pro-apoptotic stimuli. Bioorg Med Chem 18: 3823-3833.
33. + channel (SK2 channel) results in action potential prolongation in atrial myocytes and atrial fibrillation. J Physiol 587: 1087-1100.
34. Lipinski CA, Lombardo F, Dominy BW, and Feeney PJ (2001) Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 46: 3-26.
35. Meseguer V, Karashima Y, Talavera K, D'Hoedt D, Donovan-Rodríguez T, Viana F, Nilius B, and Voets T (2008) Transient receptor potential channels in sensory neurons are targets of the antimycotic agent clotrimazole. J Neurosci 28: 576-586.
36. + channel SK3 and connexin40 in arteriolar dilations during skeletal muscle contraction. FASEB J 24: 3572-3579.
37. Ca channels, increases coronary flow in male and female rat hearts. Cardiovasc Res 97: 339-348.
38. + channels, KCa3.1 and KCa2.3. PLoS ONE 8: e58614.
39. Radtke J, Schmidt K, Wulff H, Köhler R, and de Wit C (2013) Activation of KCa3.1 by SKA-31 induces arteriolar dilatation and lowers blood pressure in normo- and hypertensive connexin40-deficient mice. Br J Pharmacol 170: 293-303.
40. + channel. J Med Chem 41: 2-5.
41. Ruggieri P, Mangino G, Fioretti B, Catacuzzeno L, Puca R, Ponti D, Miscusi M, Franciolini F, Ragona G, and Calogero A (2012) The inhibition of KCa3.1 channels activity reduces cell motility in glioblastoma derived cancer stem cells. PLoS ONE 7: e47825.
42. Sankaranarayanan A, Raman G, Busch C, Schultz T, Zimin PI, Hoyer J, Köhler R, and Wulff H (2009) Naphtho[1,2-d]thiazol-2-ylamine (SKA-31), a new activator of KCa2 and KCa3.1 potassium channels, potentiates the endothelium-derived hyper-polarizing factor response and lowers blood pressure. Mol Pharmacol 75: 281-295.
43. Shakkottai VG, do Carmo Costa M, Dell'Orco JM, Sankaranarayanan A, Wulff H, and Paulson HL (2011) Early changes in cerebellar physiology accompany motor dysfunction in the polyglutamine disease spinocerebellar ataxia type 3. J Neurosci 31: 13002-13014.
44. Soder RP, Parajuli SP, Hristov KL, Rovner ES, and Petkov GV (2013) SK channel-selective opening by SKA-31 induces hyperpolarization and decreases contractility in human urinary bladder smooth muscle. Am J Physiol Regul Integr Comp Physiol 304:R155-R163.
45. Ca3.1 channel inhibitor prevents T-cell activation and inflammation in a rat model of inflammatory bowel disease. Br J Pharmacol 168: 432-444.
46. + (SK3) channels modulates arterial tone and blood pressure. Circ Res 93: 124-131.
47. Ca3.1 blocker, TRAM-34, prevents acute angioplasty-induced coronary smooth muscle phenotypic modulation and limits stenosis. Arterioscler Thromb Vasc Biol 28: 1084-1089.
48. Toyama K, Wulff H, Chandy KG, Azam P, Raman G, Saito T, Fujiwara Y, Mattson DL, Das S, and Melvin JE et al. (2008) The intermediate-conductance calcium-activated potassium channel KCa3.1 contributes to atherogenesis in mice and humans. J Clin Invest 118: 3025-3037.
49. + channels SK1, SK2, and SK3 in mouse atrial and ventricular myocytes. Am J Physiol Heart Circ Physiol 289:H2714-H2723.
50. Valero MS, Pereboom D, Barcelo-Batllory S, Brines L, Garay RP, and Alda JO (2011) Protein kinase A signalling is involved in the relaxant responses to the selective β-oestrogen receptor agonist diarylpropionitrile in rat aortic smooth muscle in vitro. J Pharm Pharmacol 63: 222-229.
51. Ca3.1 channel-blockade attenuates airway pathophysiology in a sheep model of chronic asthma. PLoS ONE 8: e66886.
52. + channel, mIK1. Roles in regulatory volume decrease and erythroid differentiation. J Biol Chem 273: 21542-21553.
53. Wei AD, Gutman GA, Aldrich R, Chandy KG, Grissmer S, and Wulff H (2005) International Union of Pharmacology. LII. Nomenclature and molecular relationships of calcium-activated potassium channels. Pharmacol Rev 57: 463-472.
54. + channel complementary DNA. Neuroscience 50: 935-946.
55. Wulff H and Castle NA (2010) Therapeutic potential of KCa3.1 blockers: an overview of recent advances, and promising trends. Expert Rev Clin Pharmacol 3: 385-396.
56. Wulff H, Gutman GA, Cahalan MD, and Chandy KG (2001) Delineation of the clotrimazole/TRAM-34 binding site on the intermediate conductance calcium-activated potassium channel, IKCa1. J Biol Chem 276: 32040-32045.
57. Wulff H and Köhler R (2013) Endothelial small- and intermediate-conductance KCa channels: an update on their pharmacology and usefulness as cardiovascular targets. J Cardiovasc Pharmacol 61: 102-112.
58. Wulff H, Kolski-Andreaco A, Sankaranarayanan A, Sabatier JM, and Shakkottai V (2007) Modulators of small- and intermediate-conductance calcium-activated potassium channels and their therapeutic indications. Curr Med Chem 14: 1437-1457.
59. + channel, IKCa1: A potential immunosuppressant. Proc Natl Acad Sci USA 97: 8151-8156.
60. 2+-activated potassium channels. Nat Commun 3: 1021.
61. + (SK2) channel in atrioventricular nodes. Circ Res 102: 465-471.